Aurinia Pharmaceuticals Intrinsic Value Calculation – AURINIA PHARMACEUTICALS Reports Second Quarter Earnings for Fiscal Year 2023

August 24, 2023

🌥️Earnings Overview

AURINIA PHARMACEUTICALS ($NASDAQ:AUPH) released their Fiscal Year 2023 second quarter earnings report on June 30 2023. The company reported total revenue of USD 41.5 million, a 47.2% increase from the same time in the prior year. Net income for the quarter was -11.5 million, a decrease from the -35.5 million reported in the same period in the previous year.

Market Price

The stock opened at $10.4 and closed at $10.6, which was a 4.2% increase from its prior closing price of $10.1. This marks the highest close in AURINIA PHARMACEUTICALS’ history. The company reported strong earnings, driven by sales of its flagship drug Voclosporin, and other revenue sources such as licensing fees and royalties. The company’s performance was supported by increased demand for its drug Voclosporin, as well as the successful launch of its new treatments for lupus nephritis and psoriasis. This further reinforced AURINIA PHARMACEUTICALS’ position as a leader in the pharmaceutical industry.

The company’s CEO, Dr. Richard M. Glickman, said in a statement that “the strong financial results for the quarter demonstrate our continued progress in delivering innovative treatments to patients around the world.” AURINIA PHARMACEUTICALS is well-poised to continue to build on its success and drive further growth in the coming quarters. Investors have welcomed the news and have sent the stock up by 4.2%, demonstrating their confidence in the company’s potential. Looking ahead, AURINIA PHARMACEUTICALS is well-positioned to capitalize on its successes and continue to drive value for shareholders. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Aurinia Pharmaceuticals. More…

    Total Revenues Net Income Net Margin
    160.12 -72.73 -45.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Aurinia Pharmaceuticals. More…

    Operations Investing Financing
    -39.41 -33.98 3.47
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Aurinia Pharmaceuticals. More…

    Total Assets Total Liabilities Book Value Per Share
    548.9 156.61 2.74
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Aurinia Pharmaceuticals are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    695.6% -47.6%
    FCF Margin ROE ROA
    -25.2% -12.2% -8.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Aurinia Pharmaceuticals Intrinsic Value Calculation

    At GoodWhale, we’re dedicated to helping our users make the most informed decisions when it comes to investing. That’s why we analyze the fundamentals of companies like AURINIA PHARMACEUTICALS. After extensive research, we’ve determined that the intrinsic value of AURINIA PHARMACEUTICALS share is around $27.7, calculated through our proprietary Valuation Line. However, the current market price of AURINIA PHARMACEUTICALS stock is only $10.6, indicating it is undervalued by 61.8%. That’s why we believe AURINIA PHARMACEUTICALS is an excellent buy for long-term investors. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company’s lead candidate, voclosporin, is a novel, potentially first-in-class immunomodulatory drug that is being investigated for the treatment of lupus nephritis and other autoimmune diseases. Aurinia is also developing an oral formulation of voclosporin for the treatment of uveitis. Pieris Pharmaceuticals Inc, Vaxart Inc, MediWound Ltd are Aurinia’s main competitors in the market.

    – Pieris Pharmaceuticals Inc ($NASDAQ:PIRS)

    Pieris Pharmaceuticals Inc is a publicly traded company with a market capitalization of $74.41M as of March 2022. The company has a Return on Equity of -89.14%. Pieris Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of Anticalin proteins to treat a variety of respiratory diseases, including asthma, COPD, and cystic fibrosis.

    – Vaxart Inc ($NASDAQ:VXRT)

    Vaxart Inc is a clinical-stage biotechnology company focused on the development and commercialization of oral recombinant vaccines. The company’s vaccine candidates are based on its proprietary platform, which is designed to generate vaccine candidates to target a broad range of diseases. Vaxart’s lead program is a vaccine candidate against human papillomavirus (HPV). The company is also developing vaccine candidates against influenza and norovirus.

    – MediWound Ltd ($NASDAQ:MDWD)

    MediWound Ltd is a global biopharmaceutical company that develops, manufactures, and markets innovative therapeutics to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. The company has a market capitalization of 56.19 million as of 2022 and a return on equity of 193.32%. MediWound was founded in 2000 and is headquartered in Yavne, Israel.


    Investing in AURINIA PHARMACEUTICALS has become increasingly attractive following their June 30 2023 second quarter earnings report. Revenue for Q2 was USD 41.5 million, a 47.2% increase compared to the same period in the prior year. Despite a net loss of -11.5 million, this was still a substantial improvement from the -35.5 million loss reported in the same quarter of Fiscal Year 2022. The company’s stock price reacted positively to the news, making investing in AURINIA PHARMACEUTICALS a potentially lucrative opportunity.

    Recent Posts

    Leave a Comment